• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Aminopyridines and derivatives

Professional Introduction to Compound with CAS No. 1159815-22-1 and Product Name: 6-Cyclobutylpyridin-3-amine

The compound with the CAS number 1159815-22-1 and the product name 6-Cyclobutylpyridin-3-amine represents a significant advancement in the field of pharmaceutical chemistry. This heterocyclic amine, characterized by its cyclobutyl substituent on the pyridine ring, has garnered considerable attention due to its unique structural properties and potential applications in medicinal chemistry. The presence of the cyclobutyl group introduces steric hindrance, which can influence both the reactivity and binding affinity of the molecule, making it a valuable scaffold for drug design.

Recent research in the field of cheminformatics has highlighted the importance of 6-Cyclobutylpyridin-3-amine as a building block for developing novel therapeutic agents. The cycloalkyl substituents in heterocyclic compounds are known to modulate pharmacokinetic profiles, enhancing oral bioavailability and reducing metabolic degradation. This feature is particularly relevant in the context of drug development, where optimizing pharmacokinetic properties is crucial for achieving desired therapeutic effects.

In particular, the 6-Cyclobutylpyridin-3-amine structure has been explored in the design of kinase inhibitors, a class of drugs that play a critical role in treating various cancers and inflammatory diseases. The steric bulk provided by the cyclobutyl group can be leveraged to improve binding interactions with target enzymes, leading to higher selectivity and potency. Studies have demonstrated that modifications at the 6-position of the pyridine ring can significantly alter the pharmacological activity of small molecules, making this compound a promising candidate for further investigation.

One of the most compelling aspects of 6-Cyclobutylpyridin-3-amine is its versatility in medicinal chemistry. Researchers have utilized this compound as a precursor in synthesizing a variety of derivatives with enhanced biological activity. For instance, derivatives with additional functional groups at the 3-position of the pyridine ring have shown promising results in preclinical studies as modulators of G-protein coupled receptors (GPCRs). The ability to fine-tune the chemical structure while retaining core pharmacophoric elements makes 6-Cyclobutylpyridin-3-amine an indispensable tool in modern drug discovery.

The synthesis of 6-Cyclobutylpyridin-3-amine involves multi-step organic transformations that highlight its synthetic accessibility. Advanced catalytic methods have been employed to construct the cyclobutyl-pyridine core, ensuring high yields and purity. These synthetic strategies not only facilitate large-scale production but also open avenues for exploring novel synthetic pathways. The growing interest in flow chemistry has further enhanced the efficiency of producing such complex molecules, reducing reaction times and improving scalability.

From a computational chemistry perspective, 6-Cyclobutylpyridin-3-amine has been extensively studied using molecular modeling techniques. These studies aim to elucidate its interactions with biological targets at an atomic level, providing insights into its mechanism of action. The integration of experimental data with computational predictions has allowed researchers to validate hypotheses and optimize lead compounds more effectively. This interdisciplinary approach underscores the importance of 6-Cyclobutylpyridin-3-amine in advancing our understanding of drug-receptor interactions.

Recent advancements in biopharmaceutical technology have also contributed to the exploration of 6-Cyclobutylpyridin-3-amine in drug development pipelines. High-throughput screening (HTS) platforms have enabled rapid identification of bioactive compounds, while CRISPR-based technologies offer new ways to assess drug efficacy in vivo. These innovations have collectively accelerated the process of translating laboratory findings into clinical applications, making compounds like 6-Cyclobutylpyridin-3-amine more relevant than ever before.

The potential applications of 6-Cyclobutylpyridin-3-amine extend beyond oncology and inflammation research. Emerging evidence suggests its utility in addressing neurological disorders, where modulation of neurotransmitter systems is key. The structural features that enhance binding affinity may also contribute to improved blood-brain barrier penetration, a critical factor for central nervous system (CNS) drugs. Such possibilities highlight the broad therapeutic potential of this compound and its derivatives.

In conclusion, 6-Cyclobutylpyridin-3-amine (CAS No. 1159815-22-1) stands out as a versatile and innovative compound with significant implications for pharmaceutical research and development. Its unique structural attributes, coupled with recent advancements in synthetic and computational methodologies, position it as a cornerstone in modern drug discovery efforts. As scientists continue to unravel its full potential, we can expect further breakthroughs that will shape future therapeutic strategies across multiple disease areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)